# Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

> **NCT07241546** · PHASE2 · RECRUITING · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 36 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** ARO-RAGE
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07241546
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2027-12
- **Final completion:** 2028-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241546, "Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07241546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*